Clinical Trials Logo

Clinical Trial Summary

Mitochondrial dysfunction in skeletal muscle results in decreased muscle fatty acid oxidation, leading to conversion of fatty acids into triglycerides and its accumulation inside the muscle tissue. Moreover, in adipose tissue mitochondrial dysfunction results in decreased fatty acid oxidation and triglyceride synthesis, leading to increased circulating fatty acid concentrations, which in turn also leads to lipid accumulation inside muscle tissue. Lipid accumulation inside muscle tissue interferes with the insulin signaling pathway and causes insulin resistance. Mitochondrial dysfunction in both tissues has therefore been proposed to play an important role in insulin resistance in humans.

Pioglitazone, a thiazolidinedione, is an FDA approved medication for the treatment of type 2 diabetes. It improves muscle insulin sensitivity at least in part by lowering intramuscular lipid concentrations but the mechanism by which this occurs is unclear. In the present study, we shall therefore test the hypothesis that pioglitazone improves mitochondrial function in muscle and adipose tissue in humans who are insulin resistant.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01165190
Study type Observational
Source Arizona State University
Contact Christian Meyer, MD
Phone (480) 965-2473
Email Christian.Meyer@asu.edu
Status Recruiting
Phase N/A
Start date May 2008

See also
  Status Clinical Trial Phase
Completed NCT01952535 - A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers Phase 1
Completed NCT01196728 - Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes Phase 1
Terminated NCT00997152 - Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients Phase 2
Completed NCT02592421 - SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2 Phase 3
Completed NCT05544214 - Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects Phase 1
Completed NCT01969084 - The Effect of Linagliptin on Mitochondrial and Endothelial Function Phase 4
Terminated NCT01644201 - A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics Phase 3
Completed NCT01020123 - Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients Phase 2
Completed NCT00995787 - Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea Phase 1
Completed NCT01505426 - A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients Phase 3
Completed NCT01262586 - Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device. Phase 3
Completed NCT00561171 - Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria Phase 2
Recruiting NCT03912363 - Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids N/A
Completed NCT01868646 - Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus Phase 4
Not yet recruiting NCT06386328 - A Clinical Trial to Evaluate the Food Effect of CKD-378 Phase 1
Terminated NCT02749435 - A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus N/A
Completed NCT00894868 - Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure Phase 4
Completed NCT01255085 - Yellow Pea Protein and Fibre and Short Term Food Intake N/A
Completed NCT02156349 - A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients. N/A
Completed NCT03084965 - Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan